Annals of Surgical Oncology

, Volume 16, Issue 4, pp 1063–1064 | Cite as

Neoadjuvant Chemotherapy for Breast Cancer: Does Pretreatment Axillary Nodal Staging Improve Decision Making?

  • Charalabos Batsis
  • Dimosthenis Ziogas
  • Michael Fatouros
Breast Oncology

References

  1. 1.
    Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008;26(5):791–7. Review.Google Scholar
  2. 2.
    Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol. 2003;10:718–21.PubMedCrossRefGoogle Scholar
  3. 3.
    Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol. 2007;4(10):578–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther. Aug 2005;5(4):737–45.PubMedCrossRefGoogle Scholar
  5. 5.
    Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357(15):1555–6 author reply 1556.PubMedCrossRefGoogle Scholar
  6. 6.
    Kilbride KE, Lee MC, Nees AV, Cimmino VM, Diehl KM, Sabel MS, et al. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. Ann Surg Oncol. Nov 2008;15(11):3252–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Goldhirsch A, Wood WC, Gelber RD,, Coates AS, Thürlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Surg Oncol. 2007;18(7):1133–44.Google Scholar
  8. 8.
    Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant(primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18(12):1927–34; Epub 12 Nov 2007. Review.PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2008;358:197, author reply 198.PubMedCrossRefGoogle Scholar
  10. 10.
    Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med. 2008;358(15):1636 author reply 1636.Google Scholar
  11. 11.
    Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol. 2008;86:139–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther. 2007;6(3):308–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol. Jan 2008;15(1):21–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol. 2002;9(10):941–3.PubMedGoogle Scholar
  15. 15.
    Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol. Dec 2004;11(12):1030–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Ziogas D, Baltogiannis G, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg. 2008;247(4):714–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Liakakos T, Roukos DH. More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol. 2008;15(4):956–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol. 2002;9(9):828–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol. 2004;11:127–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol. 2007;14:2691–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol. 2002;9:220–1.PubMedCrossRefGoogle Scholar
  22. 22.
    Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther. 2006;6:931–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest. 2008;118:1590–605.PubMedCrossRefGoogle Scholar
  24. 24.
    Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn. 2008;8(5):587–97.Google Scholar
  25. 25.
    Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn. 2008;8(1):29–39.PubMedCrossRefGoogle Scholar
  26. 26.
    My genome. So, what. Nature. 6 Nov 2008;456(7218):1. Editorial.Google Scholar
  27. 27.
    Roukos DH. Twenty-One_Gene Assay: challenges and promises in translating personal genomics and whole genome scans into personalized treatment of breast cancer. J Clin Oncol. Epub ahead of print 2 Feb 2009. DOI:10.1200/JCO.2008.20.2812.
  28. 28.
    Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol. 10 Sep 2008;26(26):4360–1.PubMedCrossRefGoogle Scholar
  29. 29.
    Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218):66–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Roukos DH. Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn. Jan 2009;9(1):1–6.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Charalabos Batsis
    • 1
  • Dimosthenis Ziogas
    • 1
  • Michael Fatouros
    • 1
  1. 1.Department of Surgery, School of MedicineUniversity of IoanninaIoanninaGreece

Personalised recommendations